Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
S&E Bio Co. Ltd. operates within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 2 pending office actions. These matters are assigned to 2 distinct examiners, with LARA, CAROLINE MONSERRAT identified as the busiest examiner.
The prosecution is concentrated within 1 distinct art unit. LARA, CAROLINE MONSERRAT is responsible for 1 pending office action. Because the actions are localized in a single art unit, the legal strategy can remain consistent regarding technical standards even as it addresses the preferences of different examiners.
The presence of the pending office actions suggests an active phase of portfolio development. With the pending office action assigned to the busiest examiner, the workload is distributed among the available examiners. Practitioners should focus on the specific procedural requirements of the art unit while managing the individual feedback from the assigned examiners to ensure progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289530 | COMPOSITION FOR PROMOTING ANGIOGENESIS COMPRISING EXTRACELLULAR VESICLES DERIVED FROM THREE-DIMENSIONAL SPHEROID-TYPE CELL AGGREGATE | LARA, CAROLINE MONSERRAT | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035500 | METHOD FOR PRODUCING EXTRACELLULAR VESICLES DERIVED FROM THREE-DIMENSIONAL SPHEROID-TYPE CELL AGGREGATE | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289530 | COMPOSITION FOR PROMOTING ANGIOGENESIS COMPRISING EXTRACELLULAR VESICLES DERIVED FROM THREE-DIMENSIONAL SPHEROID-TYPE CELL AGGREGATE | LARA, CAROLINE MONSERRAT | 1633 | §103§112Other | Non-Final OA | 33d | Pending | Nov 03, 2023 |
| 18035500 | METHOD FOR PRODUCING EXTRACELLULAR VESICLES DERIVED FROM THREE-DIMENSIONAL SPHEROID-TYPE CELL AGGREGATE | SPENCE, JENNIFER SUZANNE | 1633 | §103§112DP | Final Rejection | — | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial